Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), AbbVie Inc. and Novartis AG are Dominating in the U.S. Palmoplantar Pustulosis (PPP) Market in 2019

The U.S. Palmoplantar Pustulosis (PPP) Market is expected to grow with the CAGR of 4.8% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-palmoplantar-pustulosis-ppp-market

The U.S. palmoplantar pustulosis (PPP) market is a highly consolidated market which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the U.S. palmoplantar pustulosis (PPP) market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition and agreement into the market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in November 2019, Bristol-Myers Squibb Company completed the acquisition of Celgene, which is the leading biopharma company. This acquisition boosted the company’s product portfolio including products used for treatment of oncology, hematology, immunology and cardiovascular disease. This initiative thus helped the company to earn more revenue

Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) is the dominating player in the U.S. palmoplantar pustulosis (PPP) market. The other key players existing in the palmoplantar pustulosis (PPP) market includes ANAPTYSBIO, INC., Novartis AG, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., AbbVie Inc., Bristol-Myers Squibb Company, Aristea Therapeutics, Perrigo Company plc, Ingenus Pharmaceuticals, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Teva Pharmaceutical USA (a subsidiary of Teva Pharmaceutical Industries Ltd.), F. Hoffmann-La Roche Ltd, Cosette Pharmaceuticals, Inc., WOCKHARDT, Teligent, Lupin Pharmaceuticals, Inc. (a subsidiary of LUPIN), sanofi-aventis U.S. LLC (a subsidiary of Sanofi), Bausch Health Companies Inc., Mylan N.V., The Daavlin Company, Glenmark Pharmaceutical Inc., USA (a subsidiary of Glenmark Pharmaceutical Inc.), Akorn, Incorporated, Tolmar Pharmaceuticals, Inc., Encore Dermatology, Inc., Sigmapharm Laboratories, LLC, GlaxoSmithKline plc, Amneal Pharmaceuticals LLC, Encube Ethicals among others.

U.S. Palmoplantar Pustulosis (PPP) Market

Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.):

Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) is headquartered in New Jersey, U.S. and was founded in 1961. The company is focused on providing innovative solutions for most of the devastating disease in various therapeutic areas involving cardiovascular, immunology among others. The company has multiple business segments which includes pharmaceuticals, consumer and medical devices in which pharmaceuticals is the market focused segment. The company is providing products under the categories such as cardiovascular & metabolism, immunology, infectious diseases & vaccines, neuroscience, oncology and other among which immunology is the market focused category. The company is engaged in continuous development of palmoplantar pustulosis (PPP) treatment.

For instance,

  • In October 2020, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) obtained positive data regarding the usage of tremfya (guselkumab) indicated for the treatment of psoriasis in adult patients. The data obtained suggested that the drug works by binding to the p19 sub-units that prevents the IL23 interleukin to come in contact with IL 23 receptor. This mechanism proved to be efficient in the treatment of immunodermatology diseases and thus allowed the company to penetrate its root in the palmoplantar pustulosis (PPP) market.

The company has wide presence across the Americas, Europe, Middle East and Africa and Asia-Pacific. The company has various subsidiaries such as Janssen-Cilag A/S (Denmark), Janssen Pharmaceutica (Pty.) Ltd. (South Africa), Johnson & Johnson del Perú SA (Peru), Janssen-Cilag Farmacêutica Ltda. (Brazil) and Janssen Pharmaceuticals, Inc. (U.S.) among others.

AbbVie Inc.:

AbbVie Inc. is headquartered in North Chicago, Illinois, U.S. and was founded in 2013. The company is a research-driven biopharmaceutical company having a great focus on treating diseases in order to make a remarkable impact on people's lives. The company has multiple business segments such as immunology, hematologic oncology, HCV and other key products in which the market focused segment is immunology. The company is providing products such as ANDROGEL (testosterone gel), creon (pancrelipase) delayed-release capsules, depakote (divalproex sodium) tablets, gengraf capsules (cyclosporine capsules, USP), gengraf oral solution (cyclosporine oral solution, USP), duopa (carbidopa/levodopa enteral suspension), humira (adalimumab), kaletra (lopinavir/ritonavir) tablets and kaletra (lopinavir/ritonavir) oral solution, lupron depot (leuprolide acetate for depot suspension) uro, mavyret (glecaprevir/pibrentasvir), norvir tablets (ritonavir tablets/oral solution), orilissa (elagolix) tablets, tarka (trandolapril/verapamil HCI ER) among others. The market focused products are gengraf capsules (cyclosporine capsules, USP), gengraf oral solution (cyclosporine oral solution, USP) and humira (adalimumab). The company is engaged in continuous development for palmoplantar pustulosis (PPP) treatment.

For instance,

  • In January 2018, AbbVie Inc. has updated humira (adalimumab) formulation without citrate buffer for consumption by paediatric patients in the U.S. This product formulation update has helped the company to enhance the products access to more and more people of different age groups and hence boosted the company’s sales and overall revenue.

The company has wide presence across Africa, Asia-Pacific, Europe, Latin America, Middle East, North America and South America. The company also has various subsidiary companies such as Knoll Pharmaceutical Company (New Jersey), AbbVie S.A. (Argentina), AbbVie Pty Ltd (Australia), AbbVie SA (Belgium) and AbbVie SAS (Colombia) among others.

Novartis AG:

Novartis AG is headquartered in Basel, Switzerland and was founded in 1996. The company focuses on innovating new solutions for various health care challenges. The company has multiple business segments which includes innovative medicines and sandoz in which innovative medicines is the market focused segment. The company is providing products under the categories such as cancer, cardiovascular, renal & metabolism, immunology & dermatology, ophthalmology, neuroscience and respiratory among which immunology & dermatology is the market focused category. The company is engaged in continuous development of palmoplantar pustulosis (PPP) treatment.

For instance,

  • In November 2017, Novartis AG obtained long-term efficacy data for its product Cosentyx in order to treat palmoplantar psoriasis (PPP), a disease that leads to the formation of pustules on hand and feet. This data obtained suggested that 53% and 59% of palmoplantar psoriasis (PPP) patients who have been treated with the Cosentyx achieved clear palms. Thus, the data obtained allowed the company to establish its network in the palmoplantar pustulosis (PPP) market.

The company has wide presence across Americas, Asia-Pacific, Europe, Middle East and Africa. The company also has various subsidiary companies such as Novartis Argentina S.A., Buenos Aires (Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW (Australia), Novartis Austria GmbH, Vienna (Austria), Novartis Pharma NV, Vilvoorde (Belgium) and Sandoz (China) Pharmaceutical (China) among others.